Announcements Trials
Browse Landscape

Phase

Phase NA 14Phase 2 2Phase 4 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Gynecologic 1

Conditions

Overweight 1Obesity 1Neoplasms 1Endometrial Neoplasms 1Endometrial Hyperplasia 1

Interventions

Letrozole 5Tamoxifen 4Anastrozole 4ribociclib 3exemestane 3atezolizumab 3Vancomycin 3Nivolumab 3Magnetic Resonance Spectroscopy 3Injections 3Human Papillomavirus Recombinant Vaccine nonavalent 3Dexamethasone 3Carboplatin 3trametinib 2relatlimab 2pembrolizumab 2encorafenib 2dabrafenib 2binimetinib 2asciminib 2Specimen Handling 2Rituximab 2Prednisone 2Papillomavirus Vaccines 2Oxaliplatin 2Medroxyprogesterone Acetate 2Leucovorin 2Lenalidomide 2Ipilimumab 2Immune Checkpoint Inhibitors 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Resistance Training × 90 days × Clear all
NCT07462663 2026-05-13

SHAPE-ENDO

Hospital Universitari de Bellvitge

Phase 4 Not yet recruiting
82 enrolled
GynecologicOther

Endometrial Hyperplasia, Neoplasms, Obesity, Endometrial Neoplasms, Overweight

Data powered by HemOnc (CC BY 4.0) Colophon âš¡